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Supplementary Figures 
Supplementary Fig. 1. Schematic diagram of different HOXB-AS3 transcript variants. 
Transcript variant is NR_033201.2 has been characterized in colorectal cancer, whereas variant 
NR_033202.2 is the HOXB-AS3 transcript variant that is studied in AML. Unless otherwise 
stated, all experiments in the manuscript refer to transcript variant NR_033202.2. Exons are 
depicted as boxes and introns are depicted as lines. Strand specificity of transcripts is 
annotated by the direction of arrows. The protein coding HOXB5 and HOXB6 transcripts are 
also included in the diagram for reference. 
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Supplementary Fig. 2. Expression profiling of the HOXB-AS3 lncRNA in a dataset of 
younger adult CN-AML patients by NPM1 mutation type. a, HOXB-AS3 RNA expression 
(depicted as fold change) in younger adult CN-AML patients with wild-type NPM1 (NPM1wt; 
n=140) and in those Type A NPM1 mutations (NPM1mutA; n=208). b, HOXB-AS3 RNA 
expression (depicted as fold change) in younger adult CN-AML patients with wild-type NPM1 
(NPM1wt; n=140) and in those Type B NPM1 mutations (NPM1mutA; n=15). P values were 
calculated using the Wilcoxon rank sum test. . In the figures, line in boxplots indicates the mean 
value for each population. Whiskers indicate highest and lowest values in each population. 
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Supplementary Fig. 3. Expression of the HOXB-AS3 lncRNA across healthy 
hematopoietic cells and AML subtypes. a, HOXB-AS3 RNA expression among different 
cytogenetic subtypes of AML and ALL, in CLL, CML, MDS and in healthy hematopoietic cells 
isolated from bone marrow, based on the publicly available dataset of the International 
Microarray Innovations in Leukemia Study Group. Red color indicates high and blue low 
expression here and in Figs S1B and S1C. b, HOXB-AS3 RNA expression among different 
cytogenetic AML subtypes in the publicly available dataset of The Cancer Genome Atlas 
project. c, HOXB-AS3 expression among different molecular subtypes of cytogenetically normal 
AML in the publicly available dataset of The Cancer Genome Atlas project. Figs S1A-S1C were 
acquired through the Bloodspot portal (www.bloodspot.eu). 
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Supplementary Fig. 4: Impact of HOXB-AS3 KD on the viability of OCI-AML3 cells. a, 
Apoptosis evaluation in OCI-AML3 cells treated with either non-targeting control (scramble) or 
HOXB-AS3-targeting gapmers (HOXB-AS3 KD). Apoptosis analysis was conducted with 
Annexin V and propidium iodide staining followed by flow cytometry. Results of one experiment 
are depicted as an example. b, Comparison of percentages of viable, apoptotic (early and late) 
and necrotic cells in in OCI-AML3 cells treated with either scramble or HOXB-AS3 KD. Results 
of three independent experiments are depicted. N.S., not significant. P values were calculated 
using paired two-sided t-tests. In the figures, heights of boxplots indicate mean value with 
standard deviation. Whiskers indicate highest values in each population. Source data are 
provided as a Source Data file. 
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Supplementary Fig. 5: Functional significance of HOXB-AS3 KD in AML patients with 
NPM1 wild-type (NPM1wt) and healthy hematopoietic progenitor cells. a Number of 
colonies formed by scramble versus HOXB-AS3 KD-treated, NPM1wt AML patient blasts in 
colony-forming unit assays. b, Number of total colonies formed by scramble versus HOXB-AS3 
KD-treated, CD34-selected umbilical cord blood cells, isolated from healthy donors. c-e, Results 
of b based on type of colony forming units: c, erythroid burst forming units. d, granulocyte, 
monocyte colony forming units. e, granulocyte, erythrocyte, monocyte, megakaryocyte colony 
forming units. All experiments were conducted in triplicates. N.S., not significant. P values were 
calculated using paired two-sided t-tests. In the figures, heights of boxplots indicate mean value 
with standard deviation. Whiskers indicate highest values in each population. Source data are 
provided as a Source Data file. 
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Supplementary Fig. 6: Interaction of the HOXB-AS3 long-non coding RNA with the 
transcriptome of OCI-AML3 cells. a-b, Expression levels of different protein-coding HOX 
genes in the four NPM1mut AML patient samples (scramble versus HOXB-AS3 KD). Expression 
is measured as transcripts per kilobase million (tpm). With regard to the protein coding HOX 
genes, only those that were meaningfully expressed (arbitrary cut-off of >30 tpm in at least one 
sample) are depicted. c-g, Expression levels of different protein-coding HOX genes in the OCI-
AML3 samples (scramble versus HOXB-AS3 KD). The three time points that were evaluated 
(12, 24 and 48 hours) are depicted separately. Expression is measured as transcripts per 
kilobase million (tpm). As above, only the HOX genes that had expression levels >30 tpm in at 
least one sample are depicted. In figures A-G, blue cycles represent scramble treated and 
orange squares HOXB-AS3 KD-treated blasts. h-k, Relative HOXA9, HOXA10, HOXB5, and 
HOXB6 mRNA expression in scramble versus HOXB-AS3 KD OCI-AML3 cells at 48 hours post 
transfection. Threshold cycle (Ct) values of HOX mRNA were normalized against GAPDH 
mRNA Ct values. l, Western blot detection of the HOXA9 protein levels in scramble and HOXB-
AS3 KD OCI-AML3 cells 48 hours post transfection. ACTB protein levels serve as loading 
controls between samples. P values were calculated using paired two-sided t-tests. In the 
figures, heights of boxplots indicate mean value with standard deviation. Whiskers indicate 
highest values in each population. Source data are provided as a Source Data file. 
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Supplementary Fig. 7. Specificity of the HOXB-AS3-EBP1 interaction in OCI-AML3 cells. 
RNA-Immunoprecipitation (RIP) experiments were conducted in nuclear lysates of OCI-AML3 
cells with an anti-EBP1 antibody. RNA eluates were profiled for expression levels of HOXB-AS3 
and other protein-coding (GAPDH, ACTB) and non-coding transcripts (MALAT1, U6). 
Enrichment of EBP1-immunoprecipitates is compared to IgG control. ***, P<0.005; N.S., not 
significant. P values were calculated using paired two-sided t-tests. In the figure, heights of 
boxplots indicate mean value with standard deviation. Whiskers indicate highest values in each 
population. Source data are provided as a Source Data file. 
 
 
 
 
 
 
 
 
 
 
 
  
13 
 
Supplementary Fig. 8. Preferential interaction of the HOXB-AS3 lncRNA with the p48 
isoform of the EBP1. RNA-Immunoprecipitation (RIP) experiments in nuclear lysates of K-562 
cells, which were co-transfected with either of the FLAG epitope-tagged p42 or p48 isoforms of 
EBP1 and HOXB-AS3-overexpressing vectors. RNA eluates were profiled for expression levels 
of HOXB-AS3. Enrichment of FLAG-immunoprecipitates is compared to IgG control. P values 
were calculated using paired two-sided t-tests. In the figure, heights of boxplots indicate mean 
value with standard deviation. Whiskers indicate highest values in each population. Source data 
are provided as a Source Data file. 
 
 
 
 
 
 
 
  
14 
 
 
Supplementary Fig. 9. EBP1 does not interact with the mutant NPM1 protein in the 
nucleus of OCI-AML3 cells. a, Immunoprecipitation of the EBP1 protein in nuclear lysates of 
OCI-AML3 cells followed by denaturing gel electrophoresis and western blotting (WB) for the 
EBP1 and mutant NPM1 proteins. b, Immunoprecipitation of the mutant NPM1 protein in 
nuclear lysates of OCI-AML3 cells followed by WB for the EBP1 and mutant NPM1 proteins. 
Source data are provided as a Source Data file. 
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Supplementary Fig. 10. Impact of HOXB-AS3 long non-coding RNA knock-down (KD) on 
the EBP1 RNA and EBP1 protein abundance. a, Relative EBP1 mRNA and , b, EBP1 protein 
expression in OCI AML3 cells treated with scramble versus anti-HOXB-AS3 gapmers. In Fig. b 
ACTB is used as loading control. P values were calculated using paired two-sided t-tests. In the 
figure, heights of boxplots indicate mean value with standard deviation. Whiskers indicate 
highest values of individual samples in each population. Source data are provided as a Source 
Data file. 
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Supplementary Fig. 11. Impact of HOXB-AS3 knock-down (KD) on the binding of EBP1 
protein on non-rDNA promoters. Chromatin immunoprecipitations assays were conducted 
with an EBP1 targeting antibody in scramble versus HOXB-AS3 KD treated cells followed by 
targeted profiling for the promoter region of E2F1. P values were calculated using paired two-
sided t-tests. In the figure, heights of boxplots indicate mean value with standard deviation. 
Whiskers indicate highest values in each population. Source data are provided as a Source 
Data file. 
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Supplementary Fig. 12. Impact of HOXB-AS3 knock-down (KD) on the binding of NPM1 
protein on the rDNA locus. Chromatin immunoprecipitations assays were conducted using 
NPM1-targetting antibodies in scramble versus HOXB-AS3 KD treated cells followed by 
targeted profiling for the rDNA promoter region. P values were calculated using paired two-sided 
t-tests. In the figure, heights of boxplots indicate mean value with standard deviation. Whiskers 
indicate highest values in each population. Source data are provided as a Source Data file. 
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Supplementary Fig. 13. Relative HOXB-AS3 expression in K-562 cells overexpressing 
HOXB-AS3wt or truncated HOXB-AS3 variants 1 to 5 compared to empty vector control. 
***P<0.005; ****P<0.001. P values were calculated using paired two-sided t-tests. In the figure, 
heights of boxplots indicate mean value with standard deviation. Whiskers indicate highest 
values in each population. Source data are provided as a Source Data file. 
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Supplementary Fig. 14. Identification of the HOXB-AS3 regions that mediate the 
interaction with different HOXB-AS3 binding proteins. a, NONO- and b, PHB1-targeting RIP 
experiments in K-562 cells overexpressing HOXB-AS3wt or truncated HOXB-AS3 variants 1 to 
5. The amount of HOXB-AS3 that interacted with targeted proteins is depicted as enrichment in 
comparison to the rabbit IgG control. *, P<0.05; **, P<0.01; N.S., not significant. P values were 
calculated using paired two-sided t-tests. In the figure, heights of boxplots indicate mean value 
with standard deviation. Whiskers indicate highest values in each population. Source data are 
provided as a Source Data file. 
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Supplementary Fig. 15. Figure exemplifying the gating strategy for the conducted flow 
cytometry experiments. BrdU graphs are provided as an example. a, Sideward (SSC-A) and 
forward scatter (FSC-A) settings and selection of live cells, b, c, negative control cells were 
used to set appropriate cut-offs. b, BrdU-negative cells were not labeled with BrdU but were 
stained with an anti-BrdU antibody. c, 7-AAD negative cells. d, BrdU/7-AAD-based cell cycle 
analysis of OCI-AML3 cells 
a       b 
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Supplementary Tables 
 
Supplementary Table 1: List of used oligonucleotides 
 
 a. RT-qPCR Primers 
 HOXB-AS3 
Fw_Primer 5’-CCATTCTCGATCTTTTCAAGCG-3’ 
Rev_Primer 5’-AGGTTGCTTGTCTGGAGATG-3’ 
Probe 5’-/56-FAM/CGCCTCATC/ZEN/GCTCTTATCTAAGCCC/3IABkFQ/ 
 Hoxb5os 
Fw_Primer 5’-GAAAAGGGAGAGATGGAGGG-3’ 
Rev_Primer 5’-GAGCGACAGTGAGTTTACCG-3’ 
Probe /56-FAM/CGTACTCAG/ZEN/GAGCAGGCCGAAC/3IABkFQ/ 
 5-ETS pre-rRNA 
Fw_Primer CCCTCGGTGAGAAAAGCC 
Rv_Primer CATAACGGAGGCAGAGACAG 
Probe /56-FAM/CGCCTCATC/ZEN/GCTCTTATCTAAGCCC/3IABkFQ/ 
 b. Gapmers 
Negative 
Control 
5’-+C*+G*+A*A*T*A*G*T*T*A*G*T*A*+G*+C*+G-3’ 
Anti-
NPM1mut#1 
5’-+C*+C*+A*G*A*C*A*G*A*G*A*T*C*T*T*G*A*+A*+T-3’ 
Anti-
NPM1mut#2 
5’-+C*+T*G*C*C*A*G*A*C*A*G*A*G*A*T*C*T*+T*+G-3’ 
Anti-HOXB-
AS3#1 
5’-+G*+G*A*G*G*G*A*A*T*T*G*T*A*G*+C*+G*+A-3’ 
Anti-HOXB-
AS3#2 
5’-+T*+G*/iMe-dC/G*T*T*G*T*A*T*T*G*G*T*A*T*G*+G*+G-3’ 
 c. CRISPR gRNA sequences 
Hoxb5os_1a 5’-AAAAGGGAGAGATGGAGGG-3’ 
Hoxb5os_2a 5’-TGTGTGTGTGCCCCTCAGA-3’ 
22 
 
Hoxb5os_2b 5’-CAGTGAGTTTACCGGGCTG-3’ 
Hoxb5os_2c 5’-GAGCGACAGTGAGTTTACC-3’ 
Hoxb5os_2d 5’-ACAGTGAGTTTACCGGGCT-3’ 
Aurkb_a 5’-GAAGAAGAGCCGTTTCATCG-3’ 
Aurkb_b 5’-GCCTGGAATACGCCCCTCGC-3’ 
 d. RAP Probes 
anti-HOXB-
AS3#1 
/5Biosg/GTTGGTTAGTGGGTTTTGCCAGCTCCTTGGTTGGTGGGTCCGTGGT 
GAAGGAATTGAACCGAATTTTCTGGAAACTGTTGATGTCTGCAA 
anti-HOXB-
AS3#2 
/5Biosg/AAAGACAAACCGGGTCTGTGTTCTCCTGGTTGGTTAGTGGGTTTTGC 
CAGCTCCTTGGTTGGTGGGTCCGTGGTGAAGGAATTGAACCGA 
anti-HOXB-
AS3#3 
/5Biosg/CTGTTGATGTCTGCAAGTGAGTGCCGATCCCCTCCTCCATTCTCGATC 
TTTTCAAGCGAAGTCTACCTCTGGGCTTAGATAAGAGCGATG 
anti-HOXB-
AS3#4 
/5Biosg/CGAAGTCTACCTCTGGGCTTAGATAAGAGCGATGAGGCGCTATTTTCT 
TTCATGCCCGACTCCAGGCGCCCAGGCCCGCCTGTAGTGGCTC 
anti-HOXB-
AS3#5 
/5Biosg/GGTGAGGAGGAAGCCGAGGGTCGTGGAGGCTCTACTTGGCCCTCCTT 
TCCCTTCACCCCTTGACTTTGTCTCCCTTTGTCGATAGCAAAC 
anti-HOXB-
AS3#6 
/5Biosg/TTTATTTTACTTTCTTTGTCTTAATTTATCTCGTTCTAAATTGATACAGAC 
GACCCAAATAAAACTTTAAAATAGGGGGTGGGGAAGGGA 
anti-HOXB-
AS3#7 
/5Biosg/TGAGTCCGGGAGCAAGATCCTAAGAGGTGCGAGTTTACCAGGCCGGT 
GTGGCCGCATCCCGGCCGCTCTCGGAGCCTGACCACGCCACGC 
anti-HOXB-
AS3#8 
/5Biosg/CCGGGGCTTCCTCCGAGCCTCTCTTCCCGCTCTCTGCGCCGCCGCCG 
GCAGCCTGGAACCTTCTCCGCTGGTGCGGATATCGCTGGGTTC 
anti-HOXB-
AS3#9 
/5Biosg/GTGCGGATATCGCTGGGTTCCCGGCAGCACTGGCATGTGAGGCGGTG 
GCGCTAAGGGACGTCCTGGTTTCTATAGGGCCTGGAATCTCCG 
anti-U1#1 /5Biosg/CAGGGGAAAGCGCGAACGCAGTCCCCCACTACCACAAATTATGCAGT 
CGAGTTTCCCACATTTGGGGAAATCGCAGGGGTCAGCACATCC 
anti-U1#2 /5Biosg/TTATGCAGTCGAGTTTCCCACATTTGGGGAAATCGCAGGGGTCAGCA 
CATCCGGAGTGCAATGGATAAGCCTCGCCCTGGGAAAACCACC 
 e. Overlap PCR Primers 
1st Primer_Fw 5’-GGATAGTTTGCTATCGACAAAGGGAGAC-3’ 
 
1st 5’-GTAGTGGCTCGTGAGGAGGAAGC-3’ 
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Primer_Rev  
2nd 
Primer_Fw 
5’-CCACTACTCGGCACTCACTTGCAG-3’ 
 
2nd 
Primer_Rev 
5’-GAGTGCCGAGTAGTGGCTCCATC-3’ 
 
3rd 
Primer_Fw 
5’-ACTTGCAGAACCAGGAGAACACAGAC-3’ 
 
3rd 
Primer_Rev 
5’-CTGGTTCTGCAAGTGAGTGCCGA-3’ 
 
Alt 5 end_Fw 5’-CGGCTTCCTCCTCACCAGC-3’ 
Alt 3 end_Rev 5’-CCGTCAGTTCCACTCGGTTGT-3’ 
 
Abbreviations: Fw, forward; Rev: reverse; FAM, 6-carboxyfluorescein; ZEN, ZEN internal 
quencher; 3IABkFQ, 3’ end Iowa black quencher; Biosg, biotinylated DNA base 
+, locked-nucleic acid-modified DNA base; *, phosphorothioated DNA. 
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Supplementary Table 2. Cytogenetic and gene mutational profiles of the 12 AML patients, 
whose samples were used for in vivo and in vitro experiments 
 
Patient Karyotype Genes Mutated 
pat1 46,XY[2] NPM1, TET2, IDH1 
pat2 46,XY[5] NPM1, FLT3-ITD, TET2 
pat3 46,XX[20] NPM1, DNMT3A 
pat4 46,XY[6] NPM1, FLT3-ITD, IDH1 
pat5 46,XX[20] NPM1, FLT3-ITD 
pat6 46,XX[7] NPM1, FLT3-ITD, TET2 
pat7 47,XY,+5[cp5]/46,XY[2] TET2 
pat8 45,XY,psu dic(5;17)(p15;p13)[11]/ 
46,XY,t(2;6)(q13;p25)[5]/46,XY[4] 
RUNX1 
pat9 46,XX[20] FLT3-TKD, ASXL1, DNMT3A 
pat10 46,XX,inv(16)(p13q22)[20] FLT3-TKD 
pat11 46,XX[20] FLT3-ITD, RUNX1, IDH1 
pat12 42-46,XY,add(2)(p13),del(5)(q13q31),del(9) 
(q13q22),der(11)t(11;11)(p15;q13) add(11)(q25), 
dup(11)(q14q23),del(12)(p13),-13,ins(14;?) 
(q24;?),-17,add(19)(p13.3),add(21)(p11.2)[cp8]/ 
41-46,sl,+mar[cp12].ish del(5)(EGR1-), 
der(11)t(11;11)add(11)(MLL++),dup(11)(MLL++) 
 
 
Abbreviations: FLT3-ITD, internal tandem duplications of the FLT3 gene; FLT3-TKD, tyrosine 
kinase domain mutations of the FLT3 gene 
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Supplementary Table 3. List of candidate RNA binding proteins identified to interact with the 
HOXB-AS3 or the U1 transcripts by mass spectrometry. The mean number of identified 
peptides for each candidate interacting protein is also provided. Proteins previously reported to 
interact with U1 RNA are highlighted in yellow. 
 
Putative HOXB-AS3 
interactors 
Number of 
identified peptides 
Putative U1 
interactors 
Number of 
identified peptides 
EBP1 13 RU17 20 
DHX9 9 SNRPA 12 
PHB1 9 RUXE 8 
MATR3 8 SMD2 7 
NONO 8 SMD3 7 
HMGB2 7 PLEC 5 
HNRNPU 6 DDX3X 4 
PRDX3 6 FLNB 4 
SFPQ 6 PPIB 3 
PARK7 5     
PTMA 5     
SRSF2 5     
XRCC6 5     
HNRNPH1 5     
SF3B3 4     
HNRNPC 4     
HNRNPM 4     
HNRNPK 4     
HNRNPF 4     
STIP1 4     
PCBP1 3     
TCEA1 3     
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Supplementary Table 4. List of used antibodies 
 
Antibody Provider Identifier 
Mouse Monoclonal anti-NPM1 Abcam Cat# ab10530  
Rabbit Polyclonal anti-EBP1 Abcam Cat# ab33613 
Mouse Monoclonal anti-ACTB Cell Signaling Technology Cat #58169 
Rabbit Polyclonal anti-DHX9 Abcam Cat# ab26271 
Rabbit Monoclonal anti-HOXA9 Abcam Cat# ab140631 
Rabbit Polyclonal anti-SC35 (SRSF2) Abcam Cat# ab28428 
Rabbit Polyclonal anti-nmt55/p54nrb 
(NONO) 
Abcam Cat# ab70335 
Rabbit Polyclonal anti-NPM1 mutant OriGene Cat# TA301725 
Mouse Polyclonal anti-PHB1 Cell Signaling Technology Cat# 2426S 
Rabbit Monoclonal anti-POLR1A Cell Signaling Technology Cat# 24799 
Mouse Monoclonal anti-MATR3 Millipore Sigma Cat# MABN1587 
Normal Rabbit IgG Millipore Sigma Cat# 12-370 
Normal Mouse IgG Millipore Sigma Cat# 12-371 
Mouse Monoclonal Anti-Mouse CD45.1, 
APC Conjugated 
BD Biosciences Cat# 558701 
Mouse Monoclonal Anti-Human CD45, 
Phycoerythrin Conjugated 
BD Biosciences Cat# 555483 
 
Goat anti-Rabbit IgG, IRDye 800CW 
Conjugated 
LI-COR Biosciences Cat# 925-32211 
Goat anti-Mouse IgG, IRDye 680CW 
Conjugated 
LI-COR Biosciences Cat# 925-68070 
Goat anti-Mouse IgG, Alexa Fluor 488 
Conjugated 
Thermo Fisher Scientific Cat# A-11029 
Goat anti-Rabbit IgG, Alexa Fluor 488 
Conjugated 
Cell Signaling Technology Cat# 4412 
Rabbit anti-FLAG Sigma-Aldrich Cat# F7425 
 
